Directed Graphene‐Based Nanoplatforms for Hyperthermia: Overcoming Multiple Drug Resistance

Tu, Zhaoxu; Qiao, Haishi; Yan, Yuting; Guday, Guy; Chen, Wei; Adeli, Mohsen; Haag, Rainer

doi:10.1002/anie.201804291

Cited by 82 publications

(47 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from the examples mentioned above, other PSs, such as methylene blue [ 58 ] and coumarin–5-aminolevulinic acid (ALA) [ 59 ], and photothermal agents, such as graphene [ 60 ] and metal–organic frameworks (MOFs) [ 61 ] have been successfully conjugated with TPP to achieve mitochondria-based PT for cancer treatments.…”

Section: Strategies For Mitochondria-targeted Ptmentioning

confidence: 99%

Improving the Phototherapeutic Efficiencies of Molecular and Nanoscale Materials by Targeting Mitochondria

Lin

Bao

2018

Molecules

View full text Add to dashboard Cite

Mitochondria-targeted cancer phototherapy (PT), which works by delivering photoresponsive agents specifically to mitochondria, is a powerful strategy to improve the phototherapeutic efficiency of anticancer treatments. Mitochondria play an essential role in cellular apoptosis, and are relevant to the chemoresistance of cancer cells. Furthermore, mitochondria are a major player in many cellular processes and are highly sensitive to hyperthermia and reactive oxygen species. Therefore, mitochondria serve as excellent locations for organelle-targeted phototherapy. In this review, we focus on the recent advances of mitochondria-targeting materials for mitochondria-specific PT. The combination of mitochondria-targeted PT with other anticancer strategies is also summarized. In addition, we discuss both the challenges currently faced by mitochondria-based cancer PT and the promises it holds.

show abstract

Section: Strategies For Mitochondria-targeted Ptmentioning

confidence: 99%

Improving the Phototherapeutic Efficiencies of Molecular and Nanoscale Materials by Targeting Mitochondria

Lin

Bao

2018

Molecules

View full text Add to dashboard Cite

show abstract

“…Furthermore, drug distribution efficiency from plasma to tumors is affected by some physiologic parameters, such as competitive drug uptake by liver, excretion of small molecule drugs by urine, drug inactivation by binding to proteins, and low stability of drug in fluids 3. Therefore, nanoscale drug delivery systems have been widely studied in recent years for tumor-targeted drug therapy due to their potentials to enhance and preserve the clinical therapeutic effects of chemo-drugs with less side effects by improving their protection, absorption, penetration and distribution 2, 4-6. Nanocarriers for drug delivery have several advantages 2, 7, 8: (1) protecting the drug from being degraded and prolonging the retention time in the body; (2) increasing the solubility of some hydrophobic drugs; (3) targeted delivery and controlled release of drugs by nanoparticles modification to keep the drug concentration in tumor sites and maximize therapeutic effects; (4) possibility of multiple drug delivery to achieve synergistic therapeutic response, or application of combination therapy such as chemo-photothermal therapy.…”

Section: Introductionmentioning

confidence: 99%

Recent advances of drug delivery nanocarriers in osteosarcoma treatment

Wang¹,

Hu²,

Qing³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Osteosarcoma is the most common primary malignant bone tumor mainly occurred in children and adolescence, and chemotherapy is limited for the side effects and development of drug resistance. Advances in nanotechnology and knowledge of cancer biology have led to significant improvements in developing tumor-targeted drug delivery nanocarriers, and some have even entered clinically application. Delivery of chemotherapeutic agents by functionalized smart nanocarriers could protect the drugs from rapid clearance, prolong the circulating time, and increase the drug concentration at tumor sites, thus enhancing the therapeutic efficacy and reducing side effects. Various drug delivery nanocarriers have been designed and tested for osteosarcoma treatment, but most of them are still at experimental stage, and more further studies are needed before clinical application. In this present review, we briefly describe the types of commonly used nanocarriers in osteosarcoma treatment, and discuss the strategies for osteosarcoma-targeted delivery and controlled release of drugs. The application of nanoparticles in the management of metastatic osteosarcoma is also briefly discussed. The purpose of this article is to present an overview of recent progress of nanoscale drug delivery platforms in osteosarcoma, and inspire new ideas to develop more effective therapeutic options.

show abstract

“…To date, a number of mitochondria-targeting nanomedicines or nanoparticles (NPs) have been developed [3][4][5][6]. Current ligands for the selective delivery of anticancer agents to the mitochondria of tumor cells mainly include lipophilic cations [7,8], peptides [9,10], aptamers [11], and intrinsically targetable nanoparticles [12]. In addition, among the different alternative strategies for anti-tumor treatments [13], photothermal therapy (PTT) plays an essential role as a noninvasive method for cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

Mitochondrion- and nucleus-acting polymeric nanoagents for chemo-photothermal combination therapy

et al. 2020

View full text Add to dashboard Cite

Developing intrinsically mitochondria-targetable nanosystems for subcellular structure-oriented precise cancer therapy is highly desirable. Here, we conjugate the cluster determinant 44 (CD44)-targetable hyaluronic acid (HA) with cholesterol-poly(ethylene glycol) 2k -NH 2 and mitochondria-acting IR825-NH 2 (a cyanine dye) to construct a self-assembled nanostructure (abbreviated as HA-IR825-Chol) for photothermal therapy. The HA-IR825-Chol exhibits improved photostability and desirable photothermal properties, and can rapidly and substantially enter CD44-overexpressed cancer cells and selectively accumulate in the mitochondria of the cells. Upon near-infrared laser irradiation, it can induce severe mitochondrial damage, which causes cytochrome c release and triggers cell apoptosis. Furthermore, we demonstrate the feasibility of loading the chemotherapeutics 10-hydroxycamptothecin (HCPT) into the hydrophobic cores of HA-IR825-Chol NPs for combined chemophotothermal therapy. HCPT encapsulated within HA-IR825-Chol achieves significantly increased cellular uptake and simultaneous mitochondrial and nuclear localization, leading to the release of cytochrome c from mitochondria and upregulation of cleaved caspase-3, both of which contribute to the cell apoptosis/death. In vivo experiments reveal the excellent tumor-targeting ability of HA-IR825-Chol/HCPT, ensuring the efficient tumor eradication by the chemo-photothermal therapy. This work exemplifies the development of an intrinsically mitochondria-targetable nanocarrier for precise subcellular structure-localized drug delivery, and the Chol-mediated rapid and massive endocytosis of the nanoagents may represent a robust strategy for enhancing the efficacies of nanomedicines.

show abstract

Directed Graphene‐Based Nanoplatforms for Hyperthermia: Overcoming Multiple Drug Resistance

Cited by 82 publications

References 43 publications

Improving the Phototherapeutic Efficiencies of Molecular and Nanoscale Materials by Targeting Mitochondria

Improving the Phototherapeutic Efficiencies of Molecular and Nanoscale Materials by Targeting Mitochondria

Recent advances of drug delivery nanocarriers in osteosarcoma treatment

Mitochondrion- and nucleus-acting polymeric nanoagents for chemo-photothermal combination therapy

Contact Info

Product

Resources

About